Retrospective matched-pair study shows BTX-A alters trabecular microarchitecture in bruxism, indicating normalization post-treatment.
Background/Objectives: Bruxism is a prevalent parafunctional activity that induces masticatory muscle hypertrophy and physiological mandibular bone alterations. While botulinum toxin type A (BTX-A) injections effectively reduce muscle hyperactivity, objective radiological assessment of their skeletal effects remains limited. This study aimed to quantitatively evaluate the impact of BTX-A on mandibular trabecular bone structure by assessing potential reductions in fractal dimension (FD) in bruxism patients compared to controls. Methods: This retrospective matched-pair study included 42 bruxism patients (39 females, 3 males) receiving 50 U of BTX-A in masseter muscles and 32 age-matched non-bruxism controls (30 females, 2 males). Pre- and 6-month post-treatment panoramic radiographs were analyzed. FD values were calculated from bilateral condylar neck, ramus, and angulus regions. Results: Statistically significant reductions in FD values were observed in the angulus regions post-treatment (Right: 1.3856 to 1.2995; Left: 1.3718 to 1.2529, p < 0.001). Postoperative FD values in the BTX-A group showed no significant differences when compared to the control group (p > 0.05). Conclusions: BTX-A administration leads to measurable, region-specific reductions in mandibular trabecular bone fractal dimension, particularly in the angulus. The postoperative similarity to the control group suggests a potential normalization of bone structure following treatment. These findings highlight the clinical utility of fractal analysis for monitoring osseous adaptations in neuromuscular interventions.
No takes yet. Share an insight, caveat, or question.
Yüksel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: